Assess the Efficacy and Safety of Exenatide SR for the Prevention of Diabetes After Kidney Transplantation

NCT03961256 · Completed

Last updated 2026-05-28

This clinical trial is testing whether a medication called Exenatide SR can help prevent diabetes in people who have prediabetes after receiving a kidney transplant.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 9 people

Who can join Ages 18+ · all sexes

Timeline Started 2019-05 · est. completion 2021-10

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT03961256 ↗

Description as written by the study sponsor.

Researchers are trying to determine if an anti-diabetes medication, called Exenatide SR, is well tolerated in kidney transplant patients with elevated blood glucose levels, and if it's effective in preventing diabetes.

Treatments tested

Exenatide SR Drug

Exenatide SR 2 mg subcutaneous (SQ) weekly

Main thing measured	Progression From Prediabetes to Diabetes
Sponsor	Mayo Clinic
Conditions studied	Pre Diabetes
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03961256 ↗